Board of Directors

Paul Buckman, Chairman of the Board

Mr. Buckman currently serves on the Board of Directors for a number of medical technology companies including Xtant Medical, a medical technology company serving the needs of orthopedic and neurological surgeons; Ablative Solutions Inc., founded in 2011 to address the unmet clinical need of systemic hypertension; Aortica, a company dedicated to advancing the treatment of complex abdominal aortic aneurysm (AAA) disease; Caisson Interventional, a privately held clinical-stage medical device company designing and developing a novel percutaneous mitral valve replacement system; NeuroOne; and BioStar Ventures.  Previously, Mr. Buckman also held CEO roles at Conventus Orthopaedics, a developer of a novel 3-dimensional fracture fixation technology; SentreHeart (continues as Director), Pathway Medical Technologies (sold to Bayer Healthcare in 2011), and Devax, Inc. (sold to Biosensors International).  From 2004 through 2006, Mr. Buckman served as President of the Cardiology Division of St. Jude Medical, Inc. Prior to joining St. Jude Medical, Mr. Buckman served as Chairman of the Board and CEO of ev3, LLC, a Minnesota-based cardiovascular device company that Mr. Buckman co-founded and later acquired by Covidien for $2.5B.  He also previously held the position of President of the Cardiology Division of Boston Scientific.  Mr. Buckman received a B.A. degree in Business Administration and an MBA degree from Western Michigan University.

Ronald Eibensteiner.

As the founder and sole shareholder of Wyncrest Capital, Mr. Eibensteiner has been a very active investor in the health care, telecom and software space for the past 35 years.  He currently serves on the Boards of the following companies: Miromatrix, Inc., an organ regeneration biotech firm; ReadyCredit, a provider of store value cards for the transportation industry; Kwikbit Inc., a wireless broadband provider for the telecom industry; Integrated Medical, Inc., a medical device engineering firm; and Aleran Software Inc., a cloud based management software company for the retail industry.

His past investment activities includes: co-founder of Diametries Medical, Inc., a manufacturer of blood gas diagnostic systems; a principal investor  and Board member of OnHealth Network Company, a web-based publisher of health and wellness information until its sale to WebMD; principal investor and Board member of BigCharts, Inc., a provider of financial internet content until its sale to Dow Jones MarketWatch.  He was Chairman of the Board of Prodea Software Corporation, a data-warehousing software company, until its sale to Platinum Technology, Inc.; and principal investor and Board member of Travanti Pharma, Inc., a specialty drug delivery firm, until its sale to Taikoku Pharmaceutical; and Board member of Stellant Software (Nasdaq: STEL) until its sale to Oracle Corporation.  In 1983, Mr. Eibensteiner began his career by co-founding Arden Medical Systems and served as its Chief Financial Officer until its sale to Johnson & Johnson. 
Mr. Eibensteiner, currently serves as Chairman of the Center of the American Experiment, a public policy group in Minnesota dedicated to solving some of our nation’s most pressing issues and  holds a Bachelor of Science degree in political science from the University of Minnesota.

John Erb

Mr. Erb is currently CEO and Chairman of the Board for Sunshine Heart Inc., a global medical device company involved in the treatment of heart failure.  He also currently serves as Chairman of the Board of Directors for Osprey Medical, a public ASX company.  Mr. Erb is co-founder of NuAx, Inc. (formerly Cardia Access, Inc.), a medical device company involved in developing new devices for the treatment of heart disease.  Previously, Mr. Erb served as Chairman of the Board of Directors for Vascular Solution, Inc., a public NASDAQ company, (acquired by Teleflex Incorporated), and was a board member for CryoCath Technologies (acquired by Medtronic in 2008) and SenoRx, Inc. (acquired by CR Bard in 2010).  From 2001 through 2006, Mr. Erb was Chief Executive Officer of CHF Solutions, Inc., a medical device company focused on the treatment of congestive heart failure. CHF Solutions, Inc. was acquired by Gambro. From 1997 through 2001, Mr. Erb was President and Chief Executive Officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral vascular stents. IntraTherapeutics, Inc. was acquired by Sulzer Medica.  Other previous executive experience includes Vice President of Operations for Schneider Worldwide, a division of Pfizer, Inc.; ten years with Johnson & Johnson’s Iolab Division; and the start of his career with American Hospital Supply Corporation.  Mr. Erb has a bachelor’s degree in business administration from California State University, Fullerton.


Dr. Ross brings more than 20 years of biomedical research, management and regulatory experience in regenerative medicine, biologics, and medical devices to Miromatrix including concept development, preclinical, clinical, manufacturing, and commercialization.  He has held various technical and management positions at Guidant, Athersys and SurModics.  Since coming to Miromatrix in 2010 he has been pivotal in the development, manufacturing and regulatory clearance of the innovative MIROMESH and MIRODERM product lines.  He has spearheaded development, global patent strategy, and fundraising for the revolutionary whole organ transplant program and its key decellularization technology.  Dr. Ross has over 30 patents along with scientific publications in Nature and other peer reviewed journals.  He holds a Master’s degree in Biomedical Engineering and a Ph.D. in Molecular, Cellular and Developmental Biology from the University of Minnesota. 

Mark Wagner

Mr. Wagner currently is a member of the board of directors for Minnetronix, a medical technology and innovation company with deep experience in electronic and electromechanical devices, and Alliqua Biomedical, a medical technologies company involved in bringing the latest advances in regenerative therapies to clinicians.  Previously Mr. Wagner served as President and CEO of Minnesota-based Celleration, a company commercializing therapeutic ultrasound platform for the treatment of acute and chronic wounds, until its acquisition by Alliqua in May 2015. Prior to Celleration, Mr. Wagner co-founded and served as board chairman for Orasi Medical, a University of Minnesota spinout that developed diagnostic tools for neurological diseases.  Mr. Wagner has served as President and CEO for both Reshape Medical and ProVation Medical, and as Chairman and CEO of Survivalink. Mr. Wagner’s experience also includes a number of executive leadership positions at Nellcor Puritan Bennett.  Mr. Wagner began his career at GE Healthcare where he worked in marketing, business development and finance. In addition to completing executive leadership and corporate training programs, Mr. Wagner earned a Bachelor of Science in Business Administration from the University of Southern California.